Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

304 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.
Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, Lublin FD, Drappa J, Barron G, Madani S, Ratchford JN, She D, Cimbora D, Katz E; N-MOmentum study investigators. Cree BAC, et al. Among authors: madani s. Lancet. 2019 Oct 12;394(10206):1352-1363. doi: 10.1016/S0140-6736(19)31817-3. Epub 2019 Sep 5. Lancet. 2019. PMID: 31495497 Clinical Trial.
Placebo-controlled study in neuromyelitis optica-Ethical and design considerations.
Cree BA, Bennett JL, Sheehan M, Cohen J, Hartung HP, Aktas O, Kim HJ, Paul F, Pittock S, Weinshenker B, Wingerchuk D, Fujihara K, Cutter G, Patra K, Flor A, Barron G, Madani S, Ratchford JN, Katz E. Cree BA, et al. Among authors: madani s. Mult Scler. 2016 Jun;22(7):862-72. doi: 10.1177/1352458515620934. Epub 2015 Dec 14. Mult Scler. 2016. PMID: 26666258 Free PMC article. Clinical Trial.
Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study.
Agius MA, Klodowska-Duda G, Maciejowski M, Potemkowski A, Li J, Patra K, Wesley J, Madani S, Barron G, Katz E, Flor A. Agius MA, et al. Among authors: madani s. Mult Scler. 2019 Feb;25(2):235-245. doi: 10.1177/1352458517740641. Epub 2017 Nov 16. Mult Scler. 2019. PMID: 29143550 Free PMC article. Clinical Trial.
Exotic Animal Practice in West Asia/Middle East.
Azmanis PN, Madani SA, Rostami A, Mahdi Tamimi NS, Erian MM. Azmanis PN, et al. Among authors: madani sa. Vet Clin North Am Exot Anim Pract. 2024 Apr 16:S1094-9194(24)00017-3. doi: 10.1016/j.cvex.2024.03.006. Online ahead of print. Vet Clin North Am Exot Anim Pract. 2024. PMID: 38631922 Review.
Predicting survival of patients with advanced hepatocellular carcinoma receiving combination targeted immunotherapy: an evaluation of volumetric imaging parameters.
Mohseni A, Baghdadi A, Madani SP, Shahbazian H, Mirza-Aghazadeh-Attari M, Borhani A, Afyouni S, Zandieh G, Baretti M, Kim AK, Yarchoan M, Kamel IR. Mohseni A, et al. Among authors: madani sp. Abdom Radiol (NY). 2024 Mar 28. doi: 10.1007/s00261-024-04257-0. Online ahead of print. Abdom Radiol (NY). 2024. PMID: 38546828
304 results